On November 14, 2023, Eterna Therapeutics Inc. (Company) entered into an Exclusive Amended and Restated License Agreement (A&R Agreement) with Factor Bioscience Limited (Factor) to replace in its entirety the Exclusive License Agreement dated February 20, 2023, as amended on July 12, 2023. The A&R Agreement provides for, among other things, the expansion of the Company?s license rights to include (i) know-how that is necessary or reasonably useful to practice to the licensed patents and (ii) the ability to sublicense through multiple tiers (as opposed to only permitting a direct sublicense). The A&R Agreement also provides for technology transfer to Eterna, subject to the use restrictions in the A&R Agreement and reduces the termination rights of Factor under the A&R Agreement.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 USD | -0.43% | +5.41% | +30.36% |
1st Jan change | Capi. | |
---|---|---|
+30.36% | 12.71M | |
+25.75% | 49.18B | |
+0.90% | 42.11B | |
+49.90% | 40.37B | |
-5.26% | 28.85B | |
+13.52% | 26.09B | |
-22.14% | 18.71B | |
+8.44% | 13.26B | |
+32.40% | 12.32B | |
+0.23% | 11.99B |
- Stock Market
- Equities
- ERNA Stock
- News Eterna Therapeutics Inc.
- Eterna Therapeutics Inc. Enter into an Exclusive Amended and Restated License Agreement with Factor Bioscience Limited